TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

But a Lake Worth scientist and inventor has a product on the market that he says helps athletes deal with and prevent ...

Truvada in pill form was the first prescriptive PrEP to hit the market, followed by Descovy. The injectable PrEP Apretude was approved in 2021. HIV+ Hepatitis Policy Institute’s Schmid said the ...

US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an ...

The drug offers an alternative to daily pills such as Gilead’s Truvada and its follow-on Descovy. In the Trio Health cohort being presented at IDWeek 2024, there were zero HIV diagnoses among ...

The results demonstrated the superiority of twice-yearly lenacapavir over bHIV with 96% relative risk reduction compared with nine incident cases among 1,086 individuals in the Truvada group.

The trial pitted PrEP lenacapavir against standard-of-care once-daily Truvada (emtricitabine + tenofovir disoproxil fumarate). New safety data from the trial indicated that lenacapavir was ...

Gilead’s HIV blockbuster Truvada looks set to face generic competition in the US next year, a year earlier than expected, putting the bulk of the product’s $3 billion annual sales at risk.